www.tga.gov.au

• charset: utf-8
• name: description content: We protect the health of Australians by regulating medicines and medical devices for safety, quality and effectiveness.
• name: generator content: Therapeutic Goods Administration (TGA)
• property: og:site_name content: Therapeutic Goods Administration (TGA)
• property: og:type content: article
• property: og:url content: https://www.tga.gov.au/therapeutic-goods-administration-tga
• property: og:title content: Therapeutic Goods Administration (TGA)
• property: og:description content: We protect the health of Australians by regulating medicines and medical devices for safety, quality and effectiveness.
• property: og:image content: https://www.tga.gov.au/sites/default/files/styles/landscape/public/2022-07/homepage_thumbnail-twitter-card.jpeg.webp?h=c74750f6&itok=FxPr4GU_
• property: og:image:width content: 400
• property: og:image:height content: 225
• property: article:published_time content: 2021-12-17T15:53:50+11:00
• property: article:modified_time content: 2026-06-19T16:03:42+10:00
• name: dcterms.title content: Therapeutic Goods Administration (TGA) | Australian Government Department of Health
• name: dcterms.creator content: Therapeutic Goods Administration (TGA)
• name: dcterms.description content: We protect the health of Australians by regulating medicines and medical devices for safety, quality and effectiveness.
• name: dcterms.publisher content: Therapeutic Goods Administration (TGA)
• name: dcterms.date content: 2026-06-20T12:21+10:00
• name: dcterms.type content: text
• name: dcterms.format content: text/html
• name: dcterms.identifier content: https://www.tga.gov.au/therapeutic-goods-administration-tga
• name: dcterms.language content: en
• name: Generator content: Drupal 11 (http://drupal.org) + GovCMS (http://govcms.gov.au)
• name: MobileOptimized content: width
• name: HandheldFriendly content: true
• name: viewport content: width=device-width, initial-scale=1.0
• name: type content: section
• name: audiences content: audience-manufacturers
• name: audiences content: audience-sponsors
• name: msapplication-TileColor content: #ffffff
• name: msapplication-config content: /themes/custom/tga/favicons/browserconfig.xml
• name: theme-color content: #ffffff

• Skip to main content
• Home
• News and events
• Contact us
• About us
• Product regulation
• Quick links
• Search our product register (ARTG)
• What's new
• Regulation essentials
• Regulations for all products
• Legislation and legislative instruments
• Ingredients and the scheduling of medicines and chemicals
• Manufacturing
• Application and market authorisation
• Labelling and packaging
• Advertising
• Import and export
• Compliance and enforcement
• Access pathways including clinical trials
• Biologicals
• Faecal microbiota transplant (FMT)
• Human cell and tissue (HCT)
• Medical devices
• Implantable devices
• In vitro diagnostic (IVD) devices
• Personal protective equipment (PPE)
• Personalised medical devices
• Software and artificial intelligence (AI)
• System and procedure packs
• Medicines
• Assessed listed medicines
• Listed medicines
• Over-the-counter (OTC) medicines
• Prescription medicines
• Registered complementary medicines
• Therapeutic sunscreens
• Other therapeutic goods
• Disinfectants and sterilants
• Tampons and menstrual cups
• Unapproved therapeutic goods
• MDMA and psilocybine
• Medicinal cannabis
• Therapeutic vaping goods
• Boundary and combination products
• Safety and shortages
• Report a problem
• Report a problem or side effect
• Report a breach
• Report a medicine shortage for industry
• Manage a medical device supply disruption
• Safety monitoring and information
• Safety alerts
• Safety updates
• Shortages and supply disruptions
• Medicine shortages
• Medicine shortage alerts
• Medical device supply disruptions
• Recalls and other market actions
• Database of Recalls, Product Alerts and Product Corrections (DRAC)
• What to do if your medicine or medical device is recalled
• Market actions
• Procedure for recalls, product alerts and product corrections (PRAC)
• Recall coordinators for therapeutic goods
• Adverse events
• Medical device adverse events
• Medicine adverse events
• Database of Adverse Event Notifications (DAEN)
• Compliance actions and outcomes
• Compliance management
• Compliance priorities
• Resources and guidance
• For consumers
• Travelling with medicines and medical devices
• Vapes: information for individuals and patients
• What we regulate
• Consumer Medicine Information (CMI)
• For health professionals
• Medicine shortages: information for health professionals
• Section 19A approvals database
• Product Information (PI)
• Industry guidance and resources
• Australian Regulatory Guidelines (ARGs)
• Guidance
• International scientific guidelines adopted in Australia
• Search legislation and legislative instruments
• Business services
• TGA Business Services
• TGA Business Services: getting started with the TGA
• Enquiries about TGA Business Services portal
• TGA Business Services: how to use the portal
• TGA Business Services forms
• TGA Business Services databases
• Modernising our digital systems
• Online payment portal
• Special Access Scheme and Authorised Prescriber Scheme online system
• Authorised Prescriber
• Special Access Scheme
• Concerns regarding the public health risks associated with unapproved peptide products
• TGA releases new guidance on advertising restrictions for prescription medicines
• TGA strengthens compliance focus on unapproved peptide products as part of evolving risk response
• Medicinal cannabis hub
• Entering Australia
• Vaping hub
• Access an unapproved therapeutic good (health practitioners)
• Personalised medical devices
• Creon (pancreatic extract) capsules shortage extended
• Unapproved ibutamoren capsules (MK-677) found to contain undisclosed anabolic steroid
• Nature’s Own Glucosamine Sulfate with Chondroitin and Nature’s Own Magnesium Glycinate 1150mg
• All alerts
• Update to listed medicine ingredients in June 2026
• All news
• Consultation: Proposed amendments to the Poisons Standard - ACMS and Joint ACMS-ACCS meetings - July 2026
• Consultation on increasing transparency of Good Manufacturing Practice (GMP) inspection outcomes
• Consultation: Radiopharmaceutical regulation in Australia
• All consultations
• Accessibility
• Privacy
• Security
• Disclaimer
• Copyright
• Freedom of information
• Acronyms and glossary terms
• Search our databases
• State and territory contacts
• Email subscriptions
• http://www.tga.gov.au/#topofpage

• Open TGA Business Services portal
• Open Special Access & Authorised Prescriber Scheme portal
• Office of Drug Control
• https://www.facebook.com/TGAgovau/
• https://twitter.com/TGAgovau
• https://www.youtube.com/channel/UCem9INJbMSOeW1Ry9cNbucw
• https://instagram.com/tgagovau
• https://www.linkedin.com/company/therapeutic-goods-administration/
• Provide feedback

            Domain Name: TGA.GOV.AU

Registrar: Department of Finance

Domain Status: client delete prohibited

Domain Status: server renew prohibited

Domain Status: client update prohibited

Domain Status: auto renew period

Updated Date: 2026-04-06T00:00:25.796Z

Name Server: DNS1.SGE.NET

Name Server: DNS2.SGE.NET

Name Server: DNS3.SGE.NET

Name Server: DNS4.SGE.NET

REGISTRAR Contact: Department of Finance

>>> Last update of RDAP database: 2026-05-19T13:23:06Z